Publications by authors named "Thorsten Graef"

Claim this Profile
C
Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.
Jorge E Cortes, Brian A Jonas, Thorsten Graef, Ying Luan, Anthony S Stein

Clin Lymphoma Myeloma Leuk· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
David Hong, Drew Rasco, Michael Veeder, Jason J Luke, Jason Chandler, Thorsten Graef

Oncology· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies.
Jan A Burger, Paula Cramer, Paul M Barr, Marie-Sarah Dilhuydy, Anthony Mato, Thorsten Graef

Br J Haematol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
Jennifer R Brown, Javid Moslehi, Michael S Ewer, Susan M O'Brien, Paolo Ghia, Thorsten Graef

Br J Haematol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
Ajai Chari, Sarah Larson, Beata Holkova, Robert F Cornell, Cristina Gasparetto, Thorsten Graef

Leuk Lymphoma· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
Susan O'Brien, Peter Hillmen, Steven Coutre, Paul M Barr, Graeme Fraser, Thorsten Graef

Clin Lymphoma Myeloma Leuk· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.
Christian Buske, Shalal Sadullah, Efstathios Kastritis, Alessandra Tedeschi, Ramón García-Sanz, Thorsten Graef

Lancet Haematol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Meletios A Dimopoulos, Alessandra Tedeschi, Judith Trotman, Ramón García-Sanz, David Macdonald, Thorsten Graef

N Engl J Med· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
Paul G Richardson, William I Bensinger, Carol Ann Huff, Caitlin L Costello, Nikoletta Lendvai, Thorsten Graef

Br J Haematol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.
Norbert Vey, Thomas Prebet, Claire Thalamas, Aude Charbonnier, Jerome Rey, Thorsten Graef

Leuk Lymphoma· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.
Eric Deutsch, Elizabeth Cohen-Jonathan Moyal, Vanesa Gregorc, Paolo Andrea Zucali, Jean Menard, Thorsten Graef

Oncotarget· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.
Richard R Furman, Ying Luan, Elizabeth Bilotti, Thorsten Graef

Leuk Lymphoma· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.
Vincent Ribrag, Won Seog Kim, Reda Bouabdallah, Soon Thye Lim, Bertrand Coiffier, Thorsten Graef

Haematologica· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Meletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, Jeffrey V Matous, David Macdonald, Thorsten Graef

Lancet Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.
Elizabeth Bilotti, David H Vesole, Laura McBride, Linda Schmidt, Zhijie Gao, Thorsten Graef

Clin Lymphoma Myeloma Leuk· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
David S Siegel, Meletios Dimopoulos, Sundar Jagannath, Hartmut Goldschmidt, Simon Durrant, Thorsten Graef

Clin Lymphoma Myeloma Leuk· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.
Andrew M Evens, Sriram Balasubramanian, Julie M Vose, Wael Harb, Leo I Gordon, Thorsten Graef

Clin Cancer Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Jennifer R Brown, Jacqueline C Barrientos, Paul M Barr, Ian W Flinn, Jan A Burger, Thorsten Graef

Blood· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib in previously treated Waldenström's macroglobulinemia.
Steven P Treon, Christina K Tripsas, Kirsten Meid, Diane Warren, Gaurav Varma, Thorsten Graef

N Engl J Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
Susan O'Brien, Richard R Furman, Steven E Coutre, Jeff P Sharman, Jan A Burger, Thorsten Graef

Lancet Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Meletios Dimopoulos, David S Siegel, Sagar Lonial, Junyuan Qi, Roman Hajek, Thorsten Graef

Lancet Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.
Donna M Weber, Thorsten Graef, Mohamad Hussein, Ronald M Sobecks, Gary J Schiller

Clin Lymphoma Myeloma Leuk· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3.
Hugo G Hilton, Luca Vago, Anastazia M Older Aguilar, Achim K Moesta, Thorsten Graef

J Immunol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humans differ from other hominids in lacking an activating NK cell receptor that recognizes the C1 epitope of MHC class I.
Achim K Moesta, Thorsten Graef, Laurent Abi-Rached, Anastazia M Older Aguilar, Lisbeth A Guethlein

J Immunol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C.
Thorsten Graef, Achim K Moesta, Paul J Norman, Laurent Abi-Rached, Luca Vago

J Exp Med· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis